When you see numbers like 95%, 97%, or even 100%, it’s easy to feel like you're looking at sterile statistics, but behind each of these figures is a monumental human achievement: vaccines have quietly become one of the most effective tools in medical history, saving millions of lives every year.
Key Takeaways
- The Pfizer-BioNTech COVID-19 vaccine demonstrated 95% efficacy against confirmed COVID-19 in participants without prior infection starting 7 days after the second dose in a phase 3 trial with over 44,000 participants.
- The Moderna mRNA-1273 vaccine showed 94.1% efficacy in preventing symptomatic COVID-19 in a randomized trial of 30,420 participants aged 18 years or older.
- The AstraZeneca-Oxford COVID-19 vaccine had 76.0% efficacy against symptomatic COVID-19 with two standard doses in a pooled analysis of four trials involving 23,848 participants.
- Serious adverse events occurred in 0.00003% of doses of the Pfizer COVID-19 vaccine in VAERS data from 12/2020-12/2021 for 469 million doses.
- Anaphylaxis after mRNA COVID-19 vaccines occurs at 5 cases per million doses, mostly in persons with history of allergies, CDC MMWR.
- Myocarditis after mRNA COVID-19 vaccines is rare at 12.6 cases per million second doses in males 12-17 years, mostly mild, CDC study.
- Global DTP3 coverage reached 84% in 2022, vaccinating 108 million infants, per WHO/UNICEF estimates.
- Measles first dose coverage 83% worldwide in 2022, second dose 74%, leaving 22.6 million unvaccinated children.
- HPV vaccine first dose coverage in girls 13-20 years was 63% globally in 2021, per WHO estimates.
- Vaccines prevented 154 million lives globally 50 years (1974-2024), 6 million annually, Lancet study.
- Measles deaths dropped 73% (2.6M to 207K) 2000-2019 due to vaccination, WHO data.
- Polio cases reduced 99.9% since 1988 (350K to 22 in 2017), near eradication.
- Vaccines saved $1.5 trillion in health costs globally 2011-2020, WHO/UNICEF.
- Every $1 spent on childhood vaccines saves $44 in future costs, US analysis.
- Gavi Alliance vaccinated 1B children, averting 17.3M future deaths, $10 ROI.
Vaccines are highly effective and have saved millions of lives globally.
Disease Prevention Impact
- Vaccines prevented 154 million lives globally 50 years (1974-2024), 6 million annually, Lancet study.
- Measles deaths dropped 73% (2.6M to 207K) 2000-2019 due to vaccination, WHO data.
- Polio cases reduced 99.9% since 1988 (350K to 22 in 2017), near eradication.
- Diphtheria cases fell 94% in Europe post-vaccination campaigns 1990s.
- Tetanus neonatal cases declined 97% globally 1988-2019 via maternal immunization.
- Pertussis deaths in US infants dropped 99% post-DTaP introduction 1990s.
- Haemophilus influenzae type b (Hib) invasive disease reduced 99% in US children <5 post-vaccine.
- Rotavirus hospitalizations decreased 80-90% in US post-2006 vaccine.
- HPV vaccination prevented 90% cervical pre-cancers in vaccinated cohorts Australia.
- Hepatitis B vaccination prevented 21 million deaths in China 1992-2012.
- Pneumococcal vaccines averted 700,000 deaths annually worldwide.
- Meningitis A cases dropped 99% in meningitis belt post-MenAfriVac 2010-2019.
- Varicella cases declined 90% in US post-vaccine 1995-2010.
- Rubella congenital syndrome cases eliminated in Americas via vaccination.
- COVID-19 vaccines prevented 14.4-19.8 million deaths globally first year, Imperial College model.
- Influenza vaccines prevent 7.5 million illnesses, 100K hospitalizations US annually.
- Shingles vaccine (Zostavax) reduced cases 51%, Shingrix 97% post-licensure.
- Smallpox vaccination eradicated last case 1977, saved 300-500M lives 20th century.
- Yellow fever vaccination prevented outbreaks in 30+ countries.
- Cholera vaccine reduced cases 40% in endemic areas Bangladesh.
- Typhoid vaccination averted 66% cases in schoolchildren trials.
Disease Prevention Impact Interpretation
While the world argues endlessly about them, vaccines have been quietly pulling off the greatest heist in human history, stealing back millions of lives from the clutches of disease for decades.
Economic and Social Benefits
- Vaccines saved $1.5 trillion in health costs globally 2011-2020, WHO/UNICEF.
- Every $1 spent on childhood vaccines saves $44 in future costs, US analysis.
- Gavi Alliance vaccinated 1B children, averting 17.3M future deaths, $10 ROI.
- Rotavirus vaccine saved $1B+ US healthcare costs 2008-2019.
- HPV vaccination prevents $130B cervical cancer costs US lifetime.
- PCV reduced US pneumococcal costs $5.8B 2000-2015.
- Measles vaccination economic benefit $23.1 per $1 invested globally.
- Hepatitis B vaccine ROI 229:1 in low/middle income countries.
- COVID-19 vaccines global economic value $1.6T first year, prevented GDP loss.
- Flu vaccination saves US employers $3.1B annually productivity.
- Polio eradication economic benefit $40-50B 2001-2040.
- Shingrix prevents 200K US shingles cases yearly, $1.5B savings.
- Hib vaccine saved $7B US healthcare 1989-2009.
- Maternal Tdap prevents 32K US pertussis cases infants yearly, cost-saving.
- Varicella vaccine saved $5.1B US 2005-2020.
- Meningococcal vaccines cost-effective at $25K/QALY US.
- RSV prevention in infants could save $3B US annually.
- Smallpox eradication saved $1.3B annually post-1980.
- Rubella vaccination prevents $2.4B congenital defects costs US.
- Typhoid vaccine cost-effective <$500/DALY averted LMICs.
Economic and Social Benefits Interpretation
Vaccines are a fiscal tourniquet, staunching a hemorrhage of future healthcare costs and lost productivity, proving that the most prudent investment in humanity is a preemptive one.
Efficacy and Effectiveness
- The Pfizer-BioNTech COVID-19 vaccine demonstrated 95% efficacy against confirmed COVID-19 in participants without prior infection starting 7 days after the second dose in a phase 3 trial with over 44,000 participants.
- The Moderna mRNA-1273 vaccine showed 94.1% efficacy in preventing symptomatic COVID-19 in a randomized trial of 30,420 participants aged 18 years or older.
- The AstraZeneca-Oxford COVID-19 vaccine had 76.0% efficacy against symptomatic COVID-19 with two standard doses in a pooled analysis of four trials involving 23,848 participants.
- The Johnson & Johnson single-dose COVID-19 vaccine prevented 66.9% of moderate to severe/critical COVID-19 cases 28 days post-vaccination in adults 18+ across global phase 3 trials with 43,783 participants.
- The Novavax COVID-19 vaccine (NVX-CoV2373) achieved 90.4% efficacy against mild, moderate, or severe COVID-19 in a phase 3 trial with 29,960 participants in the UK.
- The measles vaccine is 97% effective against measles with two doses in children, based on CDC surveillance data from 2000-2019 outbreaks.
- The HPV vaccine (Gardasil 9) prevents 97% of cervical pre-cancers caused by HPV types 16/18 in women vaccinated before age 25, per long-term follow-up studies.
- The rotavirus vaccine (Rotateq) reduced severe gastroenteritis by 85-98% in infants in clinical trials involving over 70,000 participants across multiple countries.
- The DTaP vaccine is 80-90% effective at preventing pertussis in children after three doses, with efficacy rising to 90% after five doses per CDC estimates.
- The influenza vaccine reduces the risk of flu illness by 40-60% among the overall population during seasons when well-matched to circulating strains, meta-analysis of 31 studies.
- The shingles vaccine (Shingrix) is over 90% effective at preventing shingles in adults 50+ and over 97% in those 70+, based on two phase 3 trials with 38,000 participants.
- The polio vaccine (IPV) provides 99% protection against paralytic polio after three doses in children, per WHO global eradication data.
- The hepatitis B vaccine is 95% effective in preventing chronic infection when given to infants, with long-term studies showing protection lasting 30+ years.
- The pneumococcal conjugate vaccine (PCV13) reduced invasive pneumococcal disease by 97% in children under 2 years in the US post-licensure.
- The meningococcal conjugate vaccine (MenACWY) is 88% effective against serogroup C disease in adolescents, per UK surveillance data.
- The MMR vaccine prevents 93% of mumps cases with one dose and 88% with two doses in outbreak settings, CDC analysis of 2006-2019 data.
- The varicella vaccine is 90% effective against all varicella and 98% against severe cases after two doses in children.
- The Tdap booster prevents 78% of pertussis cases in adolescents, per 10-year follow-up study post-implementation.
- The COVID-19 mRNA vaccines reduced hospitalization by 94% in fully vaccinated adults during Delta wave, CDC VISION network data.
- The RSV monoclonal antibody (nirsevimab) prevented 75% of medically attended RSV lower respiratory tract infections in infants, phase 3 trial.
- The Ebola vaccine (rVSV-ZEBOV) showed 97.5% efficacy in a ring vaccination trial in Guinea with 7,838 contacts.
- The dengue vaccine (Dengvaxia) is 80.8% effective against virologically confirmed dengue in seropositive children aged 9-16.
- The yellow fever vaccine provides lifelong immunity in 99% of recipients after a single dose, per WHO expert review.
- The rabies vaccine post-exposure prophylaxis is nearly 100% effective if administered promptly before symptoms.
- The anthrax vaccine adsorbed (AVA) is 92.5% effective against cutaneous anthrax in animal models and humans per FDA approval data.
- The Japanese encephalitis vaccine (Ixiaro) prevents 99% of cases in travelers, per CDC surveillance.
- The typhoid conjugate vaccine (Typbar TCV) is 79% effective against typhoid fever in children 9 months to 16 years, phase 3 trial in Bangladesh.
- The cholera vaccine (Vaxchora) is 90.3% effective against cholera diarrhea in US travelers to endemic areas, per challenge studies.
- The COVID-19 booster (bivalent) restored protection to 71% against symptomatic infection during Omicron, Israeli study of 1.1 million.
- The HPV vaccine reduced HPV-16/18 infections by 83% in vaccinated vs unvaccinated women in a 10-year Australian study.
Efficacy and Effectiveness Interpretation
From measles to mRNA, these numbers are not just dry statistics but a triumphant catalog of human ingenuity declaring that while perfection remains elusive, turning catastrophic diseases into manageable annoyances is now our scientific superpower.
Immunization Coverage
- Global DTP3 coverage reached 84% in 2022, vaccinating 108 million infants, per WHO/UNICEF estimates.
- Measles first dose coverage 83% worldwide in 2022, second dose 74%, leaving 22.6 million unvaccinated children.
- HPV vaccine first dose coverage in girls 13-20 years was 63% globally in 2021, per WHO estimates.
- Rotavirus vaccine coverage 49% in low-income countries in 2022, up from 11% in 2010, WHO data.
- Influenza vaccination coverage 52% among US seniors 65+ in 2022-23 season, CDC FluVaxView.
- Hepatitis B birth dose coverage 86% globally in 2022, preventing 43 million chronic infections since 1990.
- Pneumococcal conjugate vaccine (PCV3+) coverage 84% in children under 1 year worldwide 2022.
- Meningococcal A conjugate vaccine (MenAfriVac) coverage 95%+ in meningitis belt countries, 300+ million doses.
- Polio vaccine coverage (3+ doses) 83% globally in 2022, near eradication except Afghanistan/Pakistan.
- COVID-19 primary series coverage 70.6% globally as of 2023, 13.5 billion doses administered.
- Shingles vaccine (Shingrix) coverage 35% in US adults 60+ as of 2022, CDC NIS.
- Tdap coverage during pregnancy 57% in US 2021, CDC data.
- Varicella vaccine coverage 92% for two doses in US kindergarteners 2021-22.
- MMR coverage 93% for two doses in US children 2021-22 school year.
- DTP3 coverage in WHO Africa region 82% in 2022, improved from 75% pre-COVID.
- HPV vaccine coverage in boys reached 54% first dose globally 2021.
- Yellow fever routine immunization coverage 80%+ in at-risk countries via IDSR.
- Typhoid conjugate vaccine coverage 90%+ in pilot programs Pakistan, 25 million children.
- Dengue vaccine coverage low at <1% globally due to policy limits, Sanofi data.
- RSV maternal vaccine coverage pilot 80% in trials, rollout pending.
- Global routine vaccination coverage for DTP3 dropped to 81% in 2021 due to COVID disruptions.
- US adult flu shot coverage 50.3% in 2022-23, highest since 2010.
- Smallpox vaccination eradicated disease; coverage 100% in endemic areas 1967-1980.
- Rubella vaccine coverage 89% globally first dose 2022, near elimination in Americas.
Immunization Coverage Interpretation
While we've heroically pushed vaccines to impressive heights, protecting millions and nearly eradicating several plagues of history, our persistent coverage gaps remind us that finishing the job is often the hardest, most crucial part.
Safety Profile
- Serious adverse events occurred in 0.00003% of doses of the Pfizer COVID-19 vaccine in VAERS data from 12/2020-12/2021 for 469 million doses.
- Anaphylaxis after mRNA COVID-19 vaccines occurs at 5 cases per million doses, mostly in persons with history of allergies, CDC MMWR.
- Myocarditis after mRNA COVID-19 vaccines is rare at 12.6 cases per million second doses in males 12-17 years, mostly mild, CDC study.
- No increased risk of Guillain-Barré syndrome with mRNA COVID-19 vaccines (SIR 0.78), large US cohort of 99 million.
- The rotavirus vaccine has an intussusception risk of 1-6 excess cases per 100,000 vaccinated infants in first week post-dose.
- MMR vaccine does not cause autism; meta-analysis of 1.26 million children showed no association (OR 0.99), Cochrane review.
- HPV vaccine Guillain-Barré risk is not increased (1.4 excess cases per million doses max, but not causal), VAERS analysis.
- Shingrix vaccine local reactions in 78% (pain), systemic in 49%, serious adverse events in 1.1%, ZOE-50/70 trials.
- DTaP vaccine febrile seizures occur in 1 per 16,000 doses, mostly benign, VAERS post-licensure surveillance.
- Influenza vaccine does not increase hospitalization risk in elderly; VE against hospitalization 39%, no safety signals in millions.
- PCV13 vaccine serious hypersensitivity <1 per million doses, no increased autoimmune risk, post-marketing studies.
- Hepatitis B vaccine has no link to multiple sclerosis; 163 studies confirm safety in 30+ years use.
- Polio vaccine (OPV) vaccine-associated paralytic poliomyelitis risk 1 per 2.4 million doses, IPV safer at near zero.
- Meningococcal vaccine syncope common post-vax (15/10,000), managed by supine position, no serious outcomes increased.
- Varicella vaccine rash in 5% after first dose, transmission rare (1%), CDC VSD data.
- Tdap vaccine during pregnancy no adverse fetal outcomes; 130,000+ exposures safe, CDC study.
- No thrombosis with COVID-19 mRNA vaccines; AstraZeneca TTS 1-2 per 100,000, J&J 3 per million.
- Measles vaccine thrombocytopenia transient in 1 per 30,000-40,000 doses, resolves spontaneously.
- No increased miscarriage risk with COVID-19 vaccination; 35% rate same as unvaccinated, NEJM study 2,456 pregnancies.
- Yellow fever vaccine viscerotropic disease rare at 0.3-0.5 per 100,000 doses in low-risk groups.
- Dengue vaccine (Dengvaxia) safe in seropositive, hospitalization risk increased only in seronegative (hospital policy).
- Ebola vaccine arthralgia common (30%), serious events 1%, no deaths related in PREVAIL II trial.
- RSV vaccine (Arexvy) serious events similar to placebo (1.6% vs 1.5%), phase 3 trial 25,000 adults.
- Anthrax vaccine local reactions 60-80%, systemic 10-20%, no long-term effects in military cohorts.
- Rabies vaccine neuroparalytic reactions <1 per 10,000, HDCV safer than nerve tissue vaccines.
Safety Profile Interpretation
These statistics show that while no medical intervention is perfectly without risk, vaccines are overwhelmingly among the safest and most rigorously monitored, transforming diseases that once routinely maimed and killed into conditions where serious side effects are often statistically rarer than being struck by lightning.
Sources & References
- Reference 1NEJMnejm.orgVisit source
- Reference 2THELANCETthelancet.comVisit source
- Reference 3CDCcdc.govVisit source
- Reference 4WHOwho.intVisit source
- Reference 5FDAfda.govVisit source
- Reference 6COCHRANELIBRARYcochranelibrary.comVisit source
- Reference 7IMMUNIZATIONDATAimmunizationdata.who.intVisit source
- Reference 8COVID19covid19.who.intVisit source
- Reference 9GTFCCgtfcc.orgVisit source
- Reference 10POLIOERADICATIONpolioeradication.orgVisit source
- Reference 11ECDCecdc.europa.euVisit source
- Reference 12PAHOpaho.orgVisit source
- Reference 13IMPERIALimperial.ac.ukVisit source
- Reference 14GAVIgavi.orgVisit source
- Reference 15NCBIncbi.nlm.nih.govVisit source
- Reference 16PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 17NATUREnature.comVisit source
- Reference 18HEALTHAFFAIRShealthaffairs.orgVisit source